Navigation Links
Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
Date:9/30/2009

either the cocaine or the methamphetamine trial. Furthermore, additional safety tests conducted in the methamphetamine trial revealed no brain or clinically significant cardiovascular abnormalities in any subject. Finally, no significant differences were found in the rates of adverse events between the CPP-109 and placebo treated subjects in either study.

Frank Vocci, Ph.D., President, Friends Research Institute and a former Director of the Division of Pharmacotherapies and Medical Consequences of the National Institute on Drug Abuse (NIDA), who participated in the experts panel, stated, "Based on expanded analyses from the Catalyst trial, compliant participants receiving vigabatrin tended to have fewer cocaine use days and generally lower cocaine metabolite levels in their urine than non-compliers. After reviewing these results and those from the recently published double-blind, placebo controlled trial conducted by Dr. Jonathan Brodie and his colleagues in Mexico, I believe CPP-109's favorable safety profile and the statistically significant 3.5 times increase in the achievement of abstinence with vigabatrin treatment that he reported, strongly support continuing the clinical development program for vigabatrin."

Patrick J. McEnany, Chief Executive Officer of Catalyst, stated, "There remains a tremendous unmet medical need for cocaine and methamphetamine addicted patients, and we believe a safe and effective patient-specific treatment may generate considerable interest among regulatory authorities, patients, physicians, investors and potential strategic partners. Our next step will be to present our findings to NIDA, the investment community, and potential strategic partners to obtain the funding to conduct additional clinical trials. We remain optimistic about the prospects for CPP-109 going forward and we are committed to aggressively pursuing our two primary objectives: (i) the continued development of CPP-109 towards a pivotal Phase
'/>"/>

SOURCE Catalyst Pharmaceutical Partners
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
2. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
3. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
6. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
7. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
8. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
9. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
10. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
11. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  According to the American ... children spend on digital devices. An AOA survey reports ... 10 and 17 estimate they use an electronic device ... separate AOA survey of parents revealed that only 40 ... device for that same amount of time. Eye doctors ...
(Date:7/22/2014)... , July 22, 2014  Vernalis plc (LSE: VER) and ... proof-of-concept (POC) for CCP-08, the third programme to ... cold collaboration. Under this collaboration, POC requires the ... human pilot comparative study against an immediate release ... Vernalis will make a milestone payment to Tris. ...
(Date:7/22/2014)... PORT WASHINGTON, New York , ... Neue Partnerschaft für umfassenden ... gefährlichen Medikamenteneinwirkungen in Österreich    ... führender Anbieter von geschlossenen Transfersystemen (Closed System ... Medikus , einen Vertriebshändler und ...
Breaking Medicine Technology:Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... Jan. 6, 2011 Lexicon Pharmaceuticals, Inc. ... on discovering breakthrough treatments for human disease, announced data ... of a solid oral dose formulation for LX4211, a ... and SGLT2). Results from the study demonstrated ...
... CHAPEL HILL, N.C., Jan. 5, 2011 The ... pipeline is pushing strategy and development executives to ... opportunity lies in combination therapies with branded products ... dose combination (FDC) products can extend a therapeutic ...
Cached Medicine Technology:Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 2Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 3Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients 4Report Highlights Successful Strategies for Bringing FDC Products to Market 2
(Date:7/22/2014)... (PRWEB) July 22, 2014 The Beryl ... and third annual Institute Scholar Program. These offerings reinforce ... the patient experience in healthcare and the need for ... The grant and scholar programs are intended ... , Value of focusing on the patient experience ...
(Date:7/22/2014)... July 22, 2014 The market for ... past few years, owing to novel medical indications created ... in the aging societies where physical appearance is extremely ... one player, current competitors, new companies and technologies are ... biosimilar BoNTs will put the price of 1st-gen products ...
(Date:7/22/2014)... CarePoint Health is pleased to announce that ... of the medical staff at Bayonne Medical Center. The election ... as voted on by the physicians on staff. The office ... relation to the administration at Bayonne Medical Center. Dr. Levine ... work to make the Medical Center the best it can ...
(Date:7/22/2014)... The Middle East Drilling fluid and Completion fluid ... fluid market in Middle East with analysis and forecast of ... East is estimated to grow from around $560 million in ... 5.7%, for the given period. , Browse through the TOC ... report, to get an idea of the in-depth analysis provided. ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Over ... in almost every sphere of human anatomy. In ... forth advancements that rendered the possibility of deploying ... including blood and tissues, in order to detect ... congenital abnormality. Essentially, In-vitro Diagnostics (IVD) have earned ...
Breaking Medicine News(10 mins):Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4Health News:Dr. Howard Levine Elected President of the Medical Staff at Bayonne Medical Center 2Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 6Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 2Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 3Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 4
... The medical community has repeatedly warned against plying young children with ... parents seem to care . Certainly not in Australia. ... extractions, dentists in that country say. ,In the ... but to remove all 20 baby teeth. ,"It's ...
... long ago there was a theory doing the rounds that ... autistic individual. This theory was not well received and ... prompted the proponents of the theory to associate the schemingly ... autism? ,Autism is a developmental disability that affects ...
... way for 70-year-old Hakimuddin of Orissa and his three ... after the impoverished man wrote to India's president ... district collector of Bhadrak in Orissa constituted a team ... on the condition of the poor family in Kamalpur ...
... common genetic variation on chromosome 9p21 is linked to a ... new international research study . The findings are published today ... an upcoming printed edition of the journal. ,Researchers ... of suffering a heart attack (myocardial infarction) and a 2.02-fold ...
... (CE-US) after a liver transplant is highly accurate in ... to a recent study. ,The study consisted ... exam after developing fluid in the abdomen and/or unclear ... serious complication in the early post transplant period, caused ...
... University researchers seem to know what makes certain babies prone ... Edinburgh University and the Royal Hospital for Sick Children in ... premature and small babies which expose them to risks of ... of the maternal and child health sciences division, are team ...
Cached Medicine News:Health News:Experts Call for Warning Lables on Fruit Juice to Save Kids' Teeth 2Health News:Diet for Autism 2Health News:Diet for Autism 3Health News:Disabled Orissa Brothers Lives Saved by Timely Intervention 2Health News:Genetic Variation is Linked to Substantial Risk in Heart Attack 2
The Perfect Single basic Vac Manifold is used to process a single 96-well plate; processing time is approximately 30 minutes....
... Perfect Single Vac Manifold is ... plate in 30 minutes; the ... "open/closed" switch and a vacuum ... operation. contains vacuum chamber, on/off ...
... automated alternative to Kuderna-Danish, Rotary, Vacuum-Style and Nitrogen Blow-Down Evaporators. For over ten years TurboVap concentration technology ... ... ... ...
Plastic Tray Type Vacuum Manifold...
Medicine Products: